-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GFNl89UhyYd8xdAZYnBY80VTbZMvtWEIj8JERDKLbC30Gr2cZz0Rm75qaiTJYTGg
 OdUxlTEFro0gFx3o+jbLPQ==

<SEC-DOCUMENT>0000950149-04-001482.txt : 20041230
<SEC-HEADER>0000950149-04-001482.hdr.sgml : 20041230
<ACCEPTANCE-DATETIME>20041230172744
ACCESSION NUMBER:		0000950149-04-001482
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20041230
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041230
DATE AS OF CHANGE:		20041230

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOTIME INC
		CENTRAL INDEX KEY:			0000876343
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943127919
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12830
		FILM NUMBER:		041234962

	BUSINESS ADDRESS:	
		STREET 1:		935 PARDEE ST
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5108459535

	MAIL ADDRESS:	
		STREET 1:		935 PARDEE STREET
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f04340e8vk.htm
<DESCRIPTION>CURRENT REPORT ON FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE
COMMISSION<br>&nbsp;</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>


<P align="center" style="font-size: 10pt"><B>CURRENT REPORT</B>



<P align="center" style="font-size: 10pt"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B>



<P align="left" style="font-size: 10pt">Date of Report (date of earliest event reported): December&nbsp;30, 2004.


<P align="center" style="font-size: 24pt"><B>BioTime, Inc.</B>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>California</B><BR>
(State or other jurisdiction<BR>
of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>1-12830</B><BR>
(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>94-3127919</B><BR>
(IRS Employer<BR>
Identification No.)</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><B>935 Pardee Street<BR>
Berkeley, California 94710</B><BR>
(Address of principal executive offices)



<P align="center" style="font-size: 10pt"><B>(510)&nbsp;845-9535</B><BR>
(Registrant&#146;s telephone number, including area code)


<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:



<P align="left" style="font-size: 10pt">&#091;&nbsp;&nbsp;&nbsp;&#093; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)


<DIV align="left" style="font-size: 10pt">&#091;&nbsp;&nbsp;&nbsp;&#093; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt">&#091;&nbsp;&nbsp;&nbsp;&#093; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
</DIV>

<DIV align="left" style="font-size: 10pt">&#091;&nbsp;&nbsp;&nbsp;&#093; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</DIV>

<DIV align="center" style="font-size: 10pt">&nbsp;
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;8.01- Other Events</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;9.01 Financial Statements and Exhibits.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="f04340exv99w1.htm">Press Release Dated December 30, 2004</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>







<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Statements made in this Report that are not historical facts may constitute
forward-looking statements that are subject to risks and uncertainties that could cause actual
results to differ materially from those discussed. Such risks and uncertainties include but are
not limited to those discussed in this report and in BioTime&#146;s Annual Report on </I><I>Form 10-K</I><I> filed
with the Securities and Exchange Commission. Words such as </I><FONT style="font-family: WP TypographicSymbols"><I>&#065;</I></FONT><I>expects,</I><FONT style="font-family: WP TypographicSymbols"><I>&#064;</I></FONT>
<FONT style="font-family: WP TypographicSymbols"><I>&#065;</I></FONT><I>may,</I><FONT style="font-family: WP TypographicSymbols"><I>&#064;</I></FONT> <FONT style="font-family: WP TypographicSymbols"><I>&#065;</I></FONT><I>will,</I><FONT style="font-family: WP TypographicSymbols"><I>&#064;</I></FONT> <FONT style="font-family: WP TypographicSymbols"><I>&#065;</I></FONT><I>anticipates,</I><FONT style="font-family: WP TypographicSymbols"><I>&#064;</I></FONT> <FONT style="font-family: WP TypographicSymbols"><I>&
#065;</I></FONT><I>intends,</I><FONT style="font-family: WP TypographicSymbols"><I>&#064;</I></FONT>
<FONT style="font-family: WP TypographicSymbols"><I>&#065;</I></FONT><I>plans,</I><FONT style="font-family: WP TypographicSymbols"><I>&#064;</I></FONT> <FONT style="font-family: WP TypographicSymbols"><I>&#065;</I></FONT><I>believes,</I><FONT style="font-family: WP TypographicSymbols"><I>&#064;</I></FONT> <FONT style="font-family: WP TypographicSymbols"><I>&#065;</I></FONT><I>seeks,</I><FONT style="font-family: WP TypographicSymbols"><I>&#064;</I></FONT> <FONT style="font-family: WP TypographicSymbols"><I>&
#065;</I></FONT><I>estimates,</I><FONT style="font-family: WP TypographicSymbols"><I>&#064;</I></FONT><I> and
similar expressions identify forward-looking statements.</I>


<P align="left" style="font-size: 10pt"><B>Section&nbsp;8- Other Events</B>


<!-- link2 "Item&nbsp;8.01- Other Events" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;8.01- Other Events</B>


<P align="left" style="font-size: 10pt">On December&nbsp;30, 2004, BioTime, Inc. issued a press release announcing that it has entered into an
agreement with Summit Pharmacueticals International Corporation, an affiliate of Sumitomo
Corporation, to develop Hextend and PentaLyte for the Japanese market. A copy of the press release
is attached as Exhibit&nbsp;99.1, which, in its entirety, is incorporated herein by reference.



<P align="left" style="font-size: 10pt"><B>Section&nbsp;9-Financial Statements and Exhibits</B>


<!-- link2 "Item&nbsp;9.01 Financial Statements and Exhibits." -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>


<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="55%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="11%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="74%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B><u>Exhibit Number</u></B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B><u>Description</u></B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release dated December&nbsp;30, 2004</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="55%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="37%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left" valign="top"><B>BIOTIME, INC.</B></TD>
</TR>

<TR valign="bottom" style="padding-top: 1em">
    <TD align="left" nowrap valign="top">Date: December 30, 2004</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Steven Seinberg
<HR size="1" noshade>
Steven Seinberg,<BR>
Chief Financial Officer</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="55%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="11%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="74%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>&nbsp;</B></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B><u>Numbers</u></B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B><u>Description</u></B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->

<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release dated December&nbsp;30, 2004</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt">3
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f04340exv99w1.htm
<DESCRIPTION>PRESS RELEASE DATED DECEMBER 30, 2004
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<p align="right" style="font-size: 10pt"><b>Exhibit 99.1</b>

<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="55%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="39%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>NEWS BULLETIN</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FROM:
<IMG src="f04340f04340.jpg" alt="(Financial relations board logo)"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">RE:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>BioTime, Inc.<br>
935 Pardee Street<br>
Berkeley, CA 94710<br>
AMEX: BTX</B></TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><HR size="1" noshade width="100%" align="center">


<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="65%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="41%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="54%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">For Further Information:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>AT THE COMPANY:<br></B>
Judith Segall<B><br></B>
Vice President of Operations<B><br></B>
The Office of the President<B><br></B>
(510)&nbsp;845-9535
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>AT FINANCIAL RELATIONS BOARD:<br></B>
Lasse Glassen<B><br></B>
Investor/Analyst Information<B><br></B>
(310)&nbsp;854-8313<B><br></B>
lglassen@financialrelationsboard.com</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><HR size="1" noshade width="100%" align="center">



<P align="left" style="font-size: 10pt"><B>FOR IMMEDIATE RELEASE<br>
December&nbsp;30, 2004</B>



<P align="center" style="font-size: 10pt"><B>BIOTIME ANNOUNCES AGREEMENT TO DEVELOP HEXTEND</B><SUP>&#174;</SUP> <B>AND<BR>
PENTALYTE</B><SUP>&#174;</SUP> <B>IN JAPAN</B>


<P align="left" style="font-size: 10pt"><B>BERKELEY, CA, December&nbsp;30, 2004 &#150; BioTime, Inc. (AMEX: BTX) </B>announced today that it has
entered into an agreement with Summit Pharmaceuticals International Corporation, an affiliate of
Sumitomo Corporation, to develop Hextend and PentaLyte for the Japanese market. Hextend and
PentaLyte are physiologically balanced blood plasma volume expanders designed for the treatment of
hypovolemia. Hypovolemia is a condition caused by low blood volume, often from blood loss during
surgery or from injury. Plasma volume expanders maintain circulatory system fluid volume and blood
pressure and keep vital organs perfused during surgery. Hextend and PentaLyte are similar
formulations, except that PentaLyte contains a lower molecular weight hydroxyethyl starch than
Hextend, and is more quickly metabolized. PentaLyte is designed for use when shorter lasting
volume expansion is desirable.


<P align="left" style="font-size: 10pt">Under the Agreement, which was signed December&nbsp;24, 2004, Summit will pay BioTime $900,000 in three
installments as partial reimbursement of BioTime&#146;s development costs of Hextend and PentaLyte.
BioTime has already received the first installment of $300,000. In addition, BioTime will pay
Summit a one-time fee of $130,000 for Summit&#146;s services in preparing a development plan for those
products in Japan. Moreover, Summit will apply for regulatory approval to manufacture and market
Hextend and PentaLyte in Japan for use at body temperatures above 12 Centigrade. Summit will begin
by preparing a development plan for Hextend. Summit will fund all laboratory, preclinical and
clinical testing and developmental activities regarding the products, and will pay all application
filing and similar fees for purposes of obtaining and maintaining regulatory approvals in Japan.


<P align="left" style="font-size: 10pt">&#147;Licensing and marketing BioTime&#146;s products in international markets is a top priority for our
Company and the agreement with Summit Pharmaceuticals International Corporation is a logical
extension of BioTime&#146;s global expansion strategy,&#148; said Judith Segall, BioTime Vice President of
Operations, Office of the President. &#147;We believe Summit&#146;s financial strength and local market
acumen coupled with BioTime&#146;s novel and innovative blood volume expanders, creates an ideal
partnership to optimize marketing opportunities for our products in Japan.&#148;



<P align="center" style="font-size: 10pt">- More -
<P align="center" style="font-size: 10pt">Financial Relations Board serves as financial relations counsel to this company, is acting on the Company&#146;s behalf in issuing this bulletin and receiving compensation therefor.
The information contained herein is furnished for information purposes only and is not to be construed as an offer to buy or sell securities.


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt">BioTime and Summit do not plan to manufacture and market Hextend and PentaLyte themselves.
Instead, they will seek to license manufacturing and marketing rights to a third party such as a
pharmaceutical company. When Hextend and PentaLyte are licensed and sold in Japan, BioTime will
receive 40% of the revenues from licensing fees, royalties, and net sales, and any other payments
made for co-development, manufacturing, or marking rights, and Summit will be entitled to the
remaining 60%. BioTime will pay to Summit 8% of all net royalties actually received by BioTime
from the sale of PentaLyte in the United States plus 8% of any license fees that BioTime receives
in consideration of granting a license to develop, manufacture and market PentaLyte in the United
States.



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>About BioTime, Inc.</I></B>

<P align="left" style="font-size: 10pt">BioTime, headquartered in Berkeley, California develops blood plasma volume expanders, blood
replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions and
technology for use in surgery, emergency trauma treatment, and other applications. Information
about BioTime can be found on the web at <u>www.biotimeinc.com.</u>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Forward Looking Statements</I></B>

<P align="left" style="font-size: 10pt">The matters discussed in this press release include forward-looking statements which are subject to
various risks, uncertainties and other factors that could cause actual results to differ materially
from the results anticipated. Such risks and uncertainties include but are not limited to the
results of clinical trials, Summit&#146;s ability to obtain regulatory approval to market Hextend and
PentaLyte in Japan; competition from products manufactured and sold or being developed by other
companies; the price of and demand for Hextend and PentaLyte; the ability of BioTime and Summit to
negotiate favorable foreign licensing or other manufacturing and marketing agreements for the
products in Japan; and the availability of reimbursement for the cost of the products and related
treatment from government health administration authorities, private health coverage insurers and
other organizations. These and other risk factors are discussed in BioTime&#146;s Annual Report on Form
10-K filed with the Securities and Exchange Commission.



<P align="center" style="font-size: 10pt"># # #




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>f04340f04340.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f04340f04340.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``,"`@,"`@,#`P,$`P,$!0@%!00$
M!0H'!P8(#`H,#`L*"PL-#A(0#0X1#@L+$!80$1,4%145#`\7&!84&!(4%13_
MVP!#`0,$!`4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P``1"`!1`,P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]4Z***`"B
ML;_A+]$_Z#6G?^!:?XT[2/$NF:\;K^S;ZWOS:R>3-]FE#['VAMO'M0!KT5GW
MNLV&ELBWE[;VKO\`=\^54W_G4]I=P7\*7%O,DT+_`'7B?<K4`6:*S_[7L/MW
MV+[;;_:\?\>WG+YG_?-.O=5LM+16O+N"U1ONM/*J9^F:`+U%5;2\@U"V2>"6
M.XA?[KQ/O5JDGG2"%I966.-%W,S?PT`3451L+^WU:RAN[*XBN;:X4/%-"^Y'
M7^\OYU8GFCMX6EE=4C0;F9_X:`)J*I6&I6FJ1M+9W,5RB_+OA</BH)-?TV&\
M^R2ZC:)<YV^2]PHD_P"^:`-2BBLC6?%6C>'C&NJ:Q8Z8[_=%W<)%N_[Z-`&O
M163IOB'3-7FEAL=0MKR:)4:1+:57*JV=O2I[W5K+2]GVR]@L]_W?/E5-WYT`
M7Z*K6=];ZC!YUM/%<1'^.)PZ_I5F@`HJAIVK6>JI(]E=17*12M`[1-NVNI^9
M/K5^@`HK(E\2:1#<-;RZI9),ORLCW"!Q^%:]`!1110`4S&]=K4^B@#Y:^'WP
MM\(:U^T'\4--O?#NG7=A8QV?V:VDMT\N+?'\^Q*]>^#_`(5\/>'[77KSPM)"
MVD:AJ#LEM!!Y4=N\2^2Z(/\`?C;\Z\AT/X;:'\1/VE/BE#KUO<3K:)9O%Y-W
M-#]^%/[CU[?\*?`/_"L_!T&@K.;F.&XN94<_W'F=U7_Q^KD1$\M_;4T>PN/A
M9%J$UG;OJ,5]##%<.GSHC_?7?[U[MHFC6.@Z9!8:;:0V%G"N([>WC"(@]E%>
M,?MI_P#)&1_V$[?_`-FKW6+[J_2E]D7VCYA_:K\+W-AXM\'>(/"5A%!XKCEN
M[QKF!!YMQY,*/L;^_P#(GZ5M_$3Q5HOQE_9CUCQ,+2":6&Q>0)*F]K6X3[^W
MWKM_B+_R6/X5?]=M2_\`26OGKXZ:7=?`>_\`%UA96[OX+\:VCB*%!\EI>=_\
M_P!QO]BKB3(^O?#&CV&@Z)9V6FVL5E9QI\D%NFU$W?-P/QKAOC_J]Q9_#^32
M+!PNK^(KB+1K1O1YCM=OP3?7HVG?\>-O_P!<D_E7AOQ$_P"$F\8_&S3K;PD-
M(>7PA9_:9CK7G>3]HN<J@!3^((A_[[J(ER+?[*.MW!\!ZAX5U!P-3\+:C-ID
MR_[&\E/_`&=/^`5[-?V%OJ5G-:74*7-M*FR6&1-RNO\`=Q7S1X&D\1_#K]IE
MX?%*Z;"WC:QW_P#$H\S[-]IA'^W_`!_(_P#WW7U'3D$3XU\&>*'^"7QP\1O]
MG2Q\`:MKDVDS>5\D%I<HB.C_`.Q]_P#[XW_W*];\2^#]#N_VCO"EQ+H]C)<3
MZ5>7,LTENA=YDDAV/G^^O]:HZ-X!L/B7H_Q;\/W^!'=>))C'+WBE\B'8X_2N
M'^!7BC6M1^,.A>%O$L+QZ[X6TR_L)IF_Y;)OA\E_^^/_`&2K)/?/C%X\'PT^
M&^M^(517N+:+;;HW\<SG9&/^^V%<'\)O@5HNH^%[7Q#XTLHO$_B?6HH[R[N=
M3C\W9O\`G2-%/W`F1TK6_:F\,77B;X(>(;>R1I)[?9>;$_B1'WO_`..;ZZ7X
M,^+K+QS\--`U.SD1P+5(940_ZJ9$"NGX'-1]D?VC.^&?P<T[X6^)O$U[HH6U
MTK6/LYCT^/=B!DW[_P`]]<I^V%HUE>_!36;^XLH)[VQ:'[//(OSP[IX0Q1_X
M,_TKUZR\1V&H:]J.D03A[_3TADN8MOW%EW[/_0'_`"KS']KG_D@'B7_?MO\`
MTICI+X@E\)WGP[T:ST/P3HMO86D-G!]DAD\JW38H=D!9J7XC>*X?`W@?6?$$
MP!^P6KR(I_C?^!?Q;:*N>#O^12T+_KP@_P#0%KRW]H!M4\5:GX4\$Z`;1]1N
M[L:K<)J!?R/LUM\^R;9\VQWV"@?V3E/V6)]4\&^*?%7@+Q!+YNH,L6N1%OXO
M-1/._5D_'?7TU7R?XZ;QM\/_`(O>"/'OB]-"CM99O[%N)-#$VSR7W_ZWS/\`
M?=_^`5]84Y"B?-/COP?H=S^UGX*AFT:QFAO=.N;FZ1[=,33;)OG?^^WR5]+5
MX'XS_P"3OOA]_P!@>Z_]!FKVE]4LEU6/3I+F(:B\33I;[QO9%^4MM]/FI2'$
MTZ***DL*8PWI_=I]1NXC0NW\-`'E?@[X'?\`"(>.+KQ2GB[6M0OK['VY+DP[
M+O:FQ-^Q!]RO5L9KR?\`X:?^%IE,4GC72HW#;,-(RX_,5U'BOXH^%O`VCVVJ
M:WK=KI^FW1Q!=R/E)/EW<,N>V:VE1K\W+*)RQQ%#EYHR,GXM_""W^+UA:V&H
M:WJ6G:?$^][6R*;)G_A9]R'I77^&M)N-%T6VLKG4KG5KB$8>\O-OFR_[VWBN
M)\/?M"?#_P`6^(++1=%\1VFIZI>E_*AM@SEMB%W[?W5K3\'?&3P7\0-5GT[P
M]XAM-5OX4\V6"`MN1/4_]]"B5&M'XHA&O0G\,BAXR^$DWB_Q?I_B`^+=8TN?
M3L_9(;+R=D6]-C_?0_?K;^)?PZTSXI^$+W0-4W)#-\T<\?WX7'W'6MOQ!K^G
M^%M$O]7U&X2UT^RA>XGF?HB(,L?TK`\3_%/PUX/\*6GB74]42WT*Z:'RK[#,
MG[W[C<?PG-3&,I?"7*<(?$=7!!Y-ND7]U=M>?^`/A(_@3Q'J^KCQ/JVL3:I\
M]U'J'E;7D^0*_P`B#&$3965_PU9\)_\`H>=,_P"^F_\`B:MVO[1GPZN6TM!X
MHM(IM3A2:T@F1TDE1_N?*5K;ZIBO^?4O_`3#ZYAI?\O8_P#@1'\1O@G%\2/$
MNDZQ/XCU;39M,99K*&S,.RWDXRZ[DW9^5:]&6S=-,6T^U2//Y/D_:?\`EINV
MXW_[W>N3\=?&+P=\-#$GB3Q#9:5/."T44S[I67^\$7YMOOBK<_Q6\(0>#5\6
M'Q!9OX=(R-2BD\R'\US6/LZCC&7*;>UI<TH\QE_#SX3O\/\`5=4O4\3:MJXU
M)WGN(+WR=CS/L_??)&GS_)^M:$OPSTM_B7;>-HB\.JI9/8S(ARDZ97:S_P"T
MF./K5Y_B!X=3PC_PE']J0'0#"LXU!7W1^7_>S6?:_&#P9>^#I?%4?B"R_P"$
M=@8J^I-)MA5A[GZBCDJ?RC]K2M?F.SD&^/!Y%>-W'[.=MI>KWFH>#?%&L>"1
M>OYES::>RO;.WJ$8?+^%=7X`^,WA#XH7=]:>&=:BU2>SC2:=8XW3RT?=L)W*
M/[IJYXZ^)_A7X:1VK^)M9MM'2ZW^2UT<!]F-W_H0H]G5C+V:C[Q'M:<H>UYO
M=*'PR^$MG\-9M6N4U74=<U+5G1KV_P!3FWR/LW[/_0S2?%;X6Q_%C0TTB]UK
M4-+TUCFX@LM@%Q\Z.F_>I^Z4JWX'^+GA#XC27$?AKQ!8ZQ-;C=+%:S99%]UZ
MU4\<?&_P1\-KZ&P\1>(K'3;V5=ZV\DFZ0)_?95^ZON:OV-7FY>7W@]O0=/GY
MO=-[P=X<F\(:!;:9+JMUJ_V<;%N+S9YFW^%?D45S<?PD=/B:_C+_`(2?5GNV
MC\C[$_E>3]GW[_)^YOV;O>NTT37M/\1:7;:EI=Y!?V%PF^&YMW#HZ^H853TG
MQCI.L^(=8T2SO$FU/1O)^VVR]8?-3?'GZK67+(VYX',?%SX20?%[2[73-0UG
M4-/T^)C*T-EY7[Q^-C$NA^YS_P!]5U?AC2)M`T&TL+C4;K5YX%V->WI4S2_-
MU8J*Y[QO\9O!/P[U2*P\1^(;32;V6+SDBN2P+)SR./\`9-7_``C\3O"OCK3+
MK4=`UVRU2SMO]?);3!Q$<?Q?W:OV=7EYN7W3/VM+FY.;WCBO%7P"7Q5XVC\4
MR>,=>T_4X$>*U-F\2?9D;.43Y/\`:K8\'?"$^%?%B^(KGQ5K?B2^6R>R0:I,
MCJJ.Z/QM0?W!5"']J+X5--Y1\;Z4C[MF'FV\_C7IEA?VVJ6<%U:3QW-O*N^.
M6%]Z,O\`LL.M.=*K2^./+\B:5:E5_ARYB]1116)U!2'H:6HW.U"?O4"9\0)\
M3?"_@OQ)\>]#URUGU"[UK5FMM/L8+.2;[7*T+(D8;9L5RWJ:Z;XB>$]4\%_L
M!R:1KBE-6M-,MUEB9O\`5#[6C+'G_83"_A46B_![6OB-)\7M)U[PMJ?AZW\3
M7AU71[^\6']Q*F-F[8[X?>W3^YNK3^(/_"Q_B!^S/J'A/5O`FKOXSF2"RED1
M[9X)W1U?SP_G?=*Q]?[[`5]?.5)U:2A+[4.;WO[JV_&Y\3"-94ZO/'[,N7W?
M[W]6.T\"?$;1/B#\0/"VEGPSJ=C<Z5H\VIVUWJMK+:.K_);-L1P-ZE9G^:JO
M[.I7_A;'QNX_YF%,>W[NM7PQXN\4ZKXJ\)6Y^'&J:%#$'MM0U?5A;-LM_)<[
M$=)G?YYDAKB/AIK7C'P%XX^(^KW'PP\275MXBU1+RU$/V/>J;-OS_OZX'&\:
ML8_R_P`W]X]!2=Z4I?S?R_W3N?VEWB\2:5X>\`M=?95\3Z@J7D@?85L8?WTV
M#[[$3_@=<_\`LQI9^.OA);>%?$*I?ZCX(UAM/?+<%[:3?;/_`+NS9C_=K+\'
M>$=8^,GQ`2_^*OP_E6&TT6*VM8K^&"2R2YW[KI]GG/AW.Q4/]Q*M?#7PAJGP
MN_:*\20:#X+O].\!ZW;Q1-)"L"6]O=P_\M40/Q"Z%O\`;W_P<U24(8:6'YO>
MC[W]?+\A.4YXJ.(Y?<E[O]?,T/!]C;M^V+X_B\F+8/#UC\NS_;JIXW\.:?X1
M_:&^`>CZ5`+?3[*VUB.*$-NV)]F2G>$1XEA_:8\2>*)_!.N6FC:MIUOIT=S*
M+?\`=O$Q^=\39V<]JL?%*R\17O[0OPZUFP\)ZOJ6E:`EXEW>6YAVG[3"B(4W
MN#A"#OZ?\"JO:_OU>7_+O_VSE(=+_9[*'_+S_P!NN4_V3;*'QO\`\)G\1=3C
M6XU[6-<N;6.:;YVM[2+8D<*_W.E8IMHOAW^T+X]\*:6HBT'Q#X4EUQ[",XBA
MN4+QNZI_#O[_`$K=\/Z7XG_9R\5>)8+#PMJ'B_P7KM[)JEHNBB-KBPN9/OQ,
MCNOR<9#Y^M,T#P+XJ:\\=?$GQ'X?N#K^KZ=_96D^';.2.6:TL_1F=T3>[_._
MST2G!5JE52]R7P_A;_P$%";I4Z7+[\?B_K^\<+^S;X@U+X2V^E^`M=N6?0O$
MVBIK/AR\D^XLSP[[FV_[Z)?\?]NM7Q-X2\1^)/V5/A-J/AS3UUJ\\/)INL-I
M3_\`+ZD,/W-G\7^Y73:G\'M4^*'[-GA[0;C3+KP[XN\/V=L-/EO"B20WENB*
M'5D9_D?9C\:O6<_COX=_!_X31Z1X?N]2NK"*U@UK2K<HLPA6U<,OS_W9-E7*
MO&=3VT>7GYM?N?Y_F1&A.%/V4N;EY?\`+_TDUO@?\2/!GQ=UG5/%6CP2Z?XG
M6TAL-5TJY^2:WV.[KE,?-\[O\]9'[:\IM_@LDFQY`FL6#[8TW,W[X<8J/X4>
M%=7\2?'G7?B7<^&+OP;IL^C)I4=I?[$N;V7SE=YW1?N<(B>^*O?M9:1K_B[P
M!I^B^'O#^H:]=3:A#=LUF8MD*0R*^'WR)RW\./2N6*IQS&ERO3W>OP_]O'4U
M5EE]3F^+WO\`M[Y'#Z?XKLO%7[4-KKT&E:AX4?2/#=QNLM9M/LEYJHR_W$_C
M1*Z?]CS2H=>^&$OCO55CO/$?BZ[N;B^O)4W-L29XDA]D`3[OO3;C1_%WQ;^-
M/@77KOP??>$=#\*)=RS3ZK+#Y]T\T>SRE2*1_D[Y-0>`[7Q?^S=%J7A>W\&Z
MIXR\)-=S7.AW>C/"TUNC_/\`9YD=TV_-G#].:Z*\H2H>RAI/W>O;FTO]S.7#
MJ<*WM9_![WV?\/V?O17^$U_9_"WXX_%GPE'*MGX2L[6'Q#%"QQ'9[TW3;0.%
M3_XBN+^$6J3^#?C=X7\67]ZK1_%*TN9+J`2[_L]SYWG6R8_A_<NB8_WZTM>^
M&WCI/#GBS6]2\.7NH>)_']W!!J%GHTT,G]EZ6CJ'@WNZ;W>'>G'RY_79^.OP
M'TO3?!6DZG\.?`$=MXQM-0M[RU;3+>"%H73Y_P!\^X?)P?N;_GV5JIX=2Y9R
M^/W?_)?_`)+\C'EQ#CS0C\/O?^3?_(_F:'[4VMV?AGX@?!S5-0>1;.TUJ9Y3
M#$\K;?*7^!/F:F?`.Y@\??''QU\0?#UE):>"=0L+:Q@N'C,0U"XC^_,JG^Y\
MZ9I?B]/XK\7>-/A5KMGX#U][?1KE]2OH4-L7B#Q[?*_UWW_E_P#'JT/`7ACQ
M-\$?BKXETS3?#E[K/P^U^?\`M*T:P>$?V;<OGS497=/D/X_PUC[D,'[/[?+_
M`#?WOS_0Z??GB^?[/-_+_=_])*_[-6BZ?K6H_&F"_LX;N"7QK?HR7$2NCIA*
M;^S0K>#?B?\`%/X<VTCOX?T:Z@O]-AD;=]F2Y3S&A3_8!Z?6L#X5:MX^^'6J
M?$"1/A9K]_-XB\076K6(:YLH45'QL29_.^3_`,?KTWX!_"O5O!,?B'Q%XIF@
MF\8>)KS[;?K;9,-N@XBA3/4(.]1B9J"J\\OB4>7\"\-"<G2Y(_#S<Q[-12"E
MKYX^H"BBB@!,48I:*`$Q1@>E+10`F!Z48&>E+10`F!Z48'I2T4`(0#U&:6BB
M@`I,"EHH`3%&*6B@!*,#TI:*`$P/2C`]*6B@!,4M%%`"8'I1BEHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
(*`"BBB@#_]D_
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
